Technical Analysis for ACLX - Arcellx, Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Weak or Absent | Up | Up | Down |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 50 DMA Support | Bullish | 0.00% | |
| Doji - Bullish? | Reversal | 0.00% | |
| 50 DMA Support | Bullish | -0.42% | |
| Doji - Bullish? | Reversal | -0.42% | |
| NR7 | Range Contraction | -1.13% | |
| Fell Below 20 DMA | Bearish | -0.69% | |
| MACD Bearish Signal Line Cross | Bearish | -0.69% | |
| Non-ADX 1,2,3,4 Bullish | Bullish Swing Setup | -0.69% | |
| Multiple of Ten Bearish | Other | -0.69% | |
| Down 3 Days in a Row | Weakness | -0.69% |
| Alert | Time |
|---|---|
| 60 Minute Opening Range Breakout | about 20 hours ago |
| 50 DMA Support | about 21 hours ago |
| 60 Minute Opening Range Breakdown | about 21 hours ago |
| Down 3% | about 21 hours ago |
| Fell Below 50 DMA | about 22 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 08/09/2024
Arcellx, Inc. Description
Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Its lead ddCAR product candidate is CART-ddBCMA, which is in Phase 1 clinical development for the treatment of patients with relapsed or refractory (r/r) multiple myeloma (MM). The company is also developing ACLX-001, an immunotherapeutic combination composed of ARC-T cells and bi-valent SparX proteins targeting BCMA to treat r/r MM; ACLX-002 and ACLX-003 for treating r/r acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS); and other AML/MDS product candidates, as well as solid tumor programs. The company was formerly known as Encarta Therapeutics, Inc. and changed its name to Arcellx, Inc. in January 2016. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Medicine Biotechnology Cancer Clinical Medicine Solid Tumors Organ Systems Acute Myeloid Leukemia Immunotherapies Multiple Myeloma Protein Kinase Inhibitor Myelodysplastic Syndrome Antibody Drug Conjugate
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 107.3699 |
| 52 Week Low | 46.43 |
| Average Volume | 572,887 |
| 200-Day Moving Average | 66.90 |
| 50-Day Moving Average | 86.77 |
| 20-Day Moving Average | 91.11 |
| 10-Day Moving Average | 95.53 |
| Average True Range | 5.04 |
| RSI (14) | 45.65 |
| ADX | 19.96 |
| +DI | 23.27 |
| -DI | 34.38 |
| Chandelier Exit (Long, 3 ATRs) | 92.24 |
| Chandelier Exit (Short, 3 ATRs) | 92.13 |
| Upper Bollinger Bands | 104.73 |
| Lower Bollinger Band | 77.48 |
| Percent B (%b) | 0.36 |
| BandWidth | 29.91 |
| MACD Line | 1.39 |
| MACD Signal Line | 2.77 |
| MACD Histogram | -1.3769 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 94.14 | ||||
| Resistance 3 (R3) | 93.73 | 91.01 | 92.98 | ||
| Resistance 2 (R2) | 91.01 | 89.25 | 91.22 | 92.60 | |
| Resistance 1 (R1) | 89.12 | 88.16 | 90.07 | 89.53 | 92.21 |
| Pivot Point | 86.40 | 86.40 | 86.88 | 86.61 | 86.40 |
| Support 1 (S1) | 84.51 | 84.64 | 85.46 | 84.92 | 82.23 |
| Support 2 (S2) | 81.79 | 83.55 | 82.00 | 81.84 | |
| Support 3 (S3) | 79.90 | 81.79 | 81.46 | ||
| Support 4 (S4) | 80.31 |
